<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827202</url>
  </required_header>
  <id_info>
    <org_study_id>EK-Nr. 011/2012</org_study_id>
    <nct_id>NCT01827202</nct_id>
  </id_info>
  <brief_title>RAS Quantification in Patients With Aliskiren or Candesartan</brief_title>
  <acronym>RASQAL</acronym>
  <official_title>Renin-Angiotensin-System Quantification in Patients Treated With Aliskiren or Candesartan (RASQAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Forced blockade of the renin-angiotensin-system (RAS) by using direct renin inhibition (DRI)&#xD;
      has long been propagated to effectuate beneficial outcomes. However, recent large clinical&#xD;
      trials have outlined harmful effects for DRI in combination with other forms of RAS blockade.&#xD;
      To date, information regarding DRI as RAS-blocking monotherapy is very limited. Furthermore,&#xD;
      it remains to be elucidated how DRI and angiotensin receptor blockers affect the so-called&#xD;
      'classical' and 'alternative' RAS molecularly. As components of the 'alternative' RAS (e.g.&#xD;
      Ang 1-7) have moved into research focus, it would be of importance to determine angiotensin&#xD;
      regulation with medical RAS blockade.&#xD;
&#xD;
      In this prospective, single-center randomized trial over 10 weeks, 24 patients with chronic&#xD;
      kidney disease (CKD) stage III-IV (eGFR 15-59 ml/min) will be randomized to take either&#xD;
      aliskiren (up to 300 mg per day) or candesartan (up to 16 mg per day) after a two week run-in&#xD;
      phase where all RAS-blockers are eliminated. The investigators will then employ a novel mass&#xD;
      spectrometry-based quantification method (after run-in and 10 weeks) to capture the&#xD;
      concentrations of ten different angiotensin peptides (including angiotensin I and II,&#xD;
      angiotensin 1-7 and angiotensin 1-5).&#xD;
&#xD;
      The investigators hypothesize that significant differences exist between angiotensin levels&#xD;
      in CKD patients with DRI compared to angiotensin receptor blockers. Specifically, the&#xD;
      investigators expect to determine the regulation of the alternative RAS represented by&#xD;
      angiotensin 1-7 with proximal versus distal blockade of the system.&#xD;
&#xD;
      Our data might contribute to a more profound understanding of results from registries and&#xD;
      clinical trials beyond the clinical effects of RAS blockade. Further, the study's results&#xD;
      might help to individualize and optimize RAS-blocking therapy strategies in CKD patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass spectrometry RAS peptide quantification</measure>
    <time_frame>2 months</time_frame>
    <description>Quantitative RAS peptide changes determined by mass spectrometry after a 2-month treatment with aliskiren or candesartan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 months</time_frame>
    <description>Blood pressure reduction, determined by ambulatory blood pressure measurements at study start and end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>2 months</time_frame>
    <description>Proteinuria reduction, measured by urinary albumin/creatinine ratio at study start and end</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypertension</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking aliskiren 150 mg once daily for 4 weeks. Thereafter, the dose will be increased to 300 mg once daily for another 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking candesartan 8 mg once daily for 4 weeks. Thereafter, the dose will be increased to 16 mg once daily for another 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RAS blockade discontinuation</intervention_name>
    <description>In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_label>Candesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Rasilez</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <arm_group_label>Candesartan</arm_group_label>
    <other_name>Atacand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic kidney disease stages III-IV (defined by modification of diet in renal disease&#xD;
             (MDRD) formula)&#xD;
&#xD;
          -  Urinary albumin to creatinine ratio (UACR) &gt;300mg/g, UACR &gt;200mg/g if already&#xD;
             receiving RAS blockade&#xD;
&#xD;
          -  Arterial hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Diabetes mellitus type 2 (defined by WHO criteria)&#xD;
&#xD;
          -  Chronic kidney disease stage V (end-stage renal disease)&#xD;
&#xD;
          -  UACR &gt;3500mg/g&#xD;
&#xD;
          -  Severe hypertension (systolic blood pressure &gt;180mmHg)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus D Saemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Marcus Saemann</investigator_full_name>
    <investigator_title>Assoc. Prof. Priv.-Doz. Dr.med.univ.</investigator_title>
  </responsible_party>
  <keyword>renin-angiotensin-system</keyword>
  <keyword>RAS blockade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

